iatroX surpasses 500,000 clinical queries and expands specialist exam coverage

LONDON - Rezul -- iatroX, the UKCA-marked, MHRA-registered clinical AI platform founded by NHS GP Dr Kola Tytler, today announced a major expansion of its educational features alongside a series of platform milestones. The platform has now answered over 500,000 clinical queries from more than 30,000 verified clinicians, with around 10% of the UK GP workforce using iatroX as monthly active users.

In internal benchmarking, iatroX records an average time-to-answer of under 20 seconds — making it the fastest clinical AI reference platform serving UK clinicians. In separate evaluation against its curated UK guideline corpus, iatroX achieved 100% information retrieval — meaning that, for the corpus tested, every clinically relevant query surfaced the correct source.

What is changing

Expanded exam coverage. iatroX has extended its educational layer to include question banks for the Specialty Certificate Examinations (SCEs) in Neurology, Endocrinology and Palliative Medicine, alongside a growing catalogue of specialist diplomas — including the DTM&H, DRCOG, DFSRH, DGM, DipIMC, DOccMed, FFICM, and the GPhC Common Registration Assessment for pharmacists (SBA, EMQ and calculation formats). Core UK exam preparation — PLAB 1, UKMLA, MRCGP AKT, MRCP Part 1, MRCEM, PANE, PSA and MSRA — remains free at the point of use, in line with the platform's founding principle that baseline clinical reference and training tools should not sit behind paywalls for NHS clinicians.

Fully cited UK-grounded retrieval. iatroX retrieves from UK national guidance — NICE, CKS, SIGN and NHS (via NHS digital) — alongside live Summary of Product Characteristics (SmPC) and dm+d data integrated via a recent partnership with Datapharm, operator of the electronic medicines compendium (emc). Every answer is fully cited and linked back to its source. The content retrieved remains proprerty of the respective publishers and iatroX assumes responsibility for all platform outputs.

More on Rezul News

• New Luxury Single Family Homes From $976,990 in Manalapan
• Longevityresearch.ca Unveils a Unique Bayesian Causal Atlas; Saves up to 7.9 life years/patient
• K2 Integrity Acquires RiskFront AI to Deliver AI Automation for Financial Crime Compliance and Risk Operations
• HousingWire acquires Keeping Current Matters, putting local market data into the tools agents use to win listings
• Turnkey Michigan City Event Venue Listed for $2.5M in Uptown Arts District

One platform across training and practice. The combination of a regulated clinical reference layer, adaptive question banks with spaced repetition, 84+ validated clinical calculators, CPD logging with FourteenFish integration, and structured differential diagnosis tooling means iatroX is now the only UK-built platform looking to span the full training-to-practice lifecycle within a single regulated environment.

Founder statement

Dr Kola Tytler, founder/developer of iatroX and a practising NHS GP, said:

"I built iatroX because the tools I needed at the desk — fast, fully cited, grounded in actual UK guidance, and useful from medical school through specialist practice — didn't exist as one product. Speed matters because no one has time to wait 90 seconds for an answer in a 10-minute consultation. Citations matter because clinicians need to see exactly where an answer comes from before they act on it. And expanding into the SCEs and the specialist diplomas reflects what our users have been asking for: a single platform that supports them through training and stays with them through practice.

We're not interested in being a thin layer over a general-purpose model, and we're not interested in being locked behind enterprise procurement cycles. iatroX is MHRA-registered, UKCA-marked, free at the point of use for individual clinicians, and grounded in regulated UK sources. The ambition is straightforward: to be the definitive clinical knowledge platform for practitioners in the UK and, in time, for English-speaking clinicians globally."

The clinical AI landscape

The clinical AI market has fragmented into distinct categories. Platforms such as OpenEvidence, free for verified US healthcare professionals, are heavily funded but centred on US evidence and US verification flows. UK-focused enterprise tools such as Medwise AI are positioned around NHS Trust deployments and integration of local Trust policies — typically procured at organisational rather than individual level.

iatroX occupies a different position: a regulated, individually accessible UK platform that is free at the point of use for clinicians, grounded in national UK guidance rather than US-centric evidence, and built to span clinical reference, exam preparation and CPD within a single environment. MHRA registration and UKCA marking are deliberate design choices — they reflect a commitment to operating as a regulated medical device rather than as a general-purpose chat tool retrofitted for healthcare.

More on Rezul News

• KIDZONET & Ocean Telecom Launch UK First eSIM Child Protection — EasySim AI Safe SIM Cards
• School Dental Screening Programs Conducted in Dubai
• British Brand Daniel Mason™ Expands Premium Braided Leather Belt Collection Internationally
• Looking for expert pool tiling in Gold Coast? Call Avid Tiling
• 15 Best Areas to Invest in Property UK in 2026 Revealed by New Investor Research

Roadmap

Over the coming quarters, iatroX will continue expanding specialist exam coverage, deepen its UK, and soon European, content partnerships, and progress work on institutional distribution to specialist training schemes, Royal Colleges and overseas medical schools. The platform's mobile applications (iOS and Android) will continue to receive feature parity with the web product, including offline calculator access and exam mode for candidates sitting timed assessments.

About iatroX

iatroX is a UKCA-marked, MHRA-registered Class I adaptive clinical AI platform built for clinicians at every stage of training and practice. Founded by serial entrepreneur Dr Kola Tytler (MBBS, CertHE, MBA, MRCGP) — an NHS GP and Forbes 30 Under 30 Europe honoree — iatroX combines a fully cited clinical Q&A engine grounded in UK national guidance (NICE, CKS, SIGN, NHS, and emc/SmPC via Datapharm) with adaptive question banks, clinical calculators, CPD logging and structured differential diagnosis tooling. The platform is free at the point of use for core UK exams and clinical reference, with premium specialist exam preparation available by subscription. iatroX has answered over 500,000 clinical queries from more than 30,000 verified clinicians, with approximately 10% of UK GPs as monthly active users.

For more information, visit https://www.iatrox.com.

Notes to editors

• iatroX is registered with the MHRA as a Class I medical device under the UKCA framework.
• The 10% of UK GPs figure refers to monthly active users measured against the UK GP workforce.
• The sub-20-second average time-to-answer and 100% information retrieval figures are based on iatroX's internal benchmarking; methodology for the retrieval evaluation is available on request.
• Total query volume (500,000+) and clinician registrations (30,000+) are based on internal platform analytics as of May 2026.
• Founder available for interview; high-resolution product imagery and founder photography available on request.